Suvretta Capital Management led a $75m Series B funding round in Veradermics.

Suvretta Capital Management, an investment management company, led a $75m Series B funding round in Veradermics, a late clinical-stage aesthetics and dermatology-focused biopharmaceutical company, with participation from Longitude Capital, Surveyor Capital, Osage University Partners, PhiFund, JW Childs Associates and Connecticut Innovations. "The initiation of our pivotal Phase 2/3 clinical trial in hair loss and completion of this $75 million financing marks a significant milestone for Veradermics. We are now well funded to advance our oral and potential best-in-class treatment for hair loss. For too long, patients have struggled with hair loss or thinning hair with inadequate results. Our team is dedicated to solving this problem with an effective and simple to use oral medication. We are grateful to our new investors and extend an especially warm welcome to Amanda and Patrick as the newest members of our Board. They both join a distinguished group of experienced life science operators and investors who share our mission to optimize better solutions for dermatologic conditions,” Reid Waldman, MD, Veradermics CEO.